Cambridge Cognition Share Discussion Threads

[bedford1976] 09/12/2024 11:50

Guess we just have to keep hoovering up the shares while the price is under the floor. I can see a good short term return on my investment here, much better than keeping the cash in the building society.

[horseyphil] 09/12/2024 10:52

Surprised that ARCHIMED hasn't made a move at this valuation - or maybe they have already? Given COG's investor relations record, I wouldn't bet on them disclosing any approaches.

ARCHIMED is now running 31 companies in the broad healthcare field, and there must be potential synergies with several of them.

[jasperlachat] 09/12/2024 10:30

I don’t think the “vultures̶1; will be waiting that long.

[bedford1976] 09/12/2024 10:26

Cogstates market cap is £200m ours is not much more than £10m. This just just goes to show how ludicrously undervalued we are being listed on AIM. Once we have built up our cash balances we need a full LSE listing.

[horseyphil] 09/12/2024 10:13

Cogstate shares are up around 20% over the past 2 weeks, albeit helped by buybacks

[bedford1976] 09/12/2024 09:59

I have topped up my holding this morning. I have a feeling this is on the move soon, and Brett Gordon purchasing adds to my belief something big (contract wise) is coming.

[40 fathoms] 09/12/2024 00:36

Another "expression of interest" job listing within the clinical team and with the same time frame just popped up. For me this pretty much confirms something of very decent size is in the pipeline.

[horseyphil] 08/12/2024 08:53

Interesting 40fathoms. Also see that there are 5 current vacancies advertised on COG's website.

[40 fathoms] 08/12/2024 00:16

Perhaps some straw to clasp! If this were a replacement hire, you would expect they would be interviewing now. So it might suggest they are anticipating significantly increased activity in Q2 next year. In which case, contracts would need to be signed in the next couple of months.

Here’s the straw: They have a good line of sight of contract wins before formalising them. If we were just talking about a normal increase in business levels, it could be managed within the existing operational capacity. To me, this suggests that something more significant might be in the works—either a couple of large trials or possibly a preferred supplier agreement with a CRO or Pharma but they do not want to pre-commit the resources until it is signed.

[jasperlachat] 05/12/2024 11:02

Yep cheers 40fathoms. Doing a better job than the company at keeping us informed. 32% down on the placing price and all we get is the CEO has gone. Time for an update now!!

[bmcollins] 01/12/2024 10:05

@40 fathoms
Yes, I agree with earwacks, thanks for keeping us in the loop on this, I certainly appreciate your posts

[40 fathoms] 01/12/2024 08:06

As a reminder, Monument Therapeutics is 22% owned by Cambridge Cognition, and we hold a 12.5% gross royalty on all income received.

Monument Therapeutics is developing two digital biomarker/drug combinations: one for neuroinflammation and the other for improving cognition in schizophrenia. It's important to note that all the APIs used by Monument are novel formulations of well-characterized CNS-active small molecules, meaning they have known safety profiles and are familiar to regulatory bodies.

Of additional interest, Dr. Stephen Brannan has recently joined their Advisory Board. He is highly regarded in neuropsychiatry and was the Chief Medical Officer at Karuna Therapeutics. He played a significant role in developing KarXT, which has just been approved by the FDA for schizophrenia, and was instrumental in Bristol Myers Squibb's $14 billion acquisition of Karuna last year.

[40 fathoms] 30/11/2024 13:54

Monument Therapeutic news ; first patient is dosed in the Phase I trail for their MT1988 API which is focused on improving cognition in schizophrenia.

[bedford1976] 28/11/2024 18:15

As of September became a Director of DP Medical Supplies according to Linkedin, and this tallies up with Companies House. Sounds like he had simply run his course at CamCog, and he already had a few irons in the fire.

[jasperlachat] 28/11/2024 12:12

Anyone know what Stork is up to, other than having a ghostly presence on the Cog sp?

[earwacks] 19/11/2024 08:55

Doubt opportunistic bid would get passed the board or top share holders. Would have to be very hostile to beat Brett for starters. Lots of interesting things happening with 🍏 I would like to know more about. Even their former broker analyst doesn’t seem to have much clue

[bedford1976] 19/11/2024 08:41

Yes Brett Gordon will be in direct contact with the board as a more or less 10 percent part owner. Indicates the share price is an anomaly and the underlying business is on target.
I think CamCog is a no brainer at the current share price. Hopefully some more buyers surface and we get a lift in the company value. My fear is we are quite vulnerable to a opportunistic bid with such a low market cap in this lucrative sector.

[earwacks] 18/11/2024 23:42

Brett Gordon can’t get enough. Moved to over 9 percent holding. Interestingly not moved the share price a jot. It’s about 100,000 shares £30ks worth. Not much but hopefully an encouraging sign. Some explaining to do to all shareholders , not just to the privileged few

[bedford1976] 18/11/2024 11:49

Yes agree the current management have got to roll their sleeves up and get some good contracts. They need to focus on generating cash now and getting into a comfortable position. No further acquisitions just a pile of cash in the bank will do nicely. .

[jasperlachat] 18/11/2024 10:00

The price is under the floor! 40% reduction in share price on the only news of Stork being chopped!!? That wasn’t quite the deal back in June, when we handed them more dosh.

[bedford1976] 15/11/2024 12:29

Topped up my holding today whilst the price is on the floor hopefully some good news coming soon on contract wins.

[40 fathoms] 07/11/2024 22:59

There are a couple of things worth noting about Monument Therapeutics:
Firstly, the valuation in the RNS and Dowgate report is based on the last funding round mark, which would be based on some degree of success. However, given the size of the markets MTx is addressing a typical risk-based DCF valuation for MTx would be enormously higher.

Secondly, MTx uses reformulated generic APIs which already approved by the FDA and are off patent, with known safety profiles and MOAs. So safety becomes much less of an issue than it would be in a new CNS focused API.

Finally, MTx's approach involves both the drug and the digital test to identify suitable patients. Cambridge Cognition owns these tests and has licensed them to MTx. These validated tests have their own distinct value. The Latent Inhibition test, for instance, is a key biomarker in many conditions beyond Schizophrina, including ADHD, depression, certain types of autism, bipolar disorder, OCD, and PTSD.